Involvement of Extracellular Signal-Regulated Kinase Activation in Human Osteosarcoma Cell Resistance to the Histone Deacetylase Inhibitor FK228 [(1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone]

The histone deacetylase inhibitor depsipeptide [(1S,4S,7Z,10S, 16E,21R)-7-ethylidene-4,21-bis(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19, 22-pentone] (FK228) has attracted a great deal of interest because of its antiproliferative and apoptotic properties in various malignancies. Histone deacetylase inhibitors induce the expression of the multidrug resistance transporter P-glycoprotein (P-gp), and FK228 is a known P-gp substrate. Thus, FK228 seems to induce its own mechanism of drug resistance by up-regulating P-gp. The goal of this study was to establish human FK228-resistant osteosarcoma cell lines and to investigate whether there are mechanisms of FK228 resistance in addition to P-gp up-regulation. After 72 h in culture, the 50% inhibitory concentrations (IC50) of FK228 were 4.8 and 991 nM in HOS and HOS/FK8 cells, respectively, and 3.6 and 1420 nM in U2OS and U2OS/FK11 cells, respectively. Increased histone H3 acetylation was observed in FK228-resistant cell lines after a 1-h treatment with 10 nM FK228. Unlike in parental cells, significant P-gp overexpression was detected in FK228-resistant cells, and 10 nM FK228 treatment activated the mitogen-activated protein kinase (MAPK) pathway but did not induce Fas ligand (FasL) up-regulation or c-FLIP down-regulation. However, treatment of FK228-resistant cells with a combination of FK228 and mitogen-activated protein kinase kinase (MEK) inhibitors induced apoptosis, up-regulated FasL, and down-regulated c-FLIP. The expression and function of P-gp were unaltered by treatment with MEK inhibitors. These results indicate that the FK228 resistance of osteosarcoma cells is related to P-gp overexpression and MAPK pathway activation by FK228. MEK or P-gp inhibitors may be useful in overcoming this resistance.

[1]  R. Larson,et al.  Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia , 2008, Clinical Cancer Research.

[2]  S. Steinberg,et al.  Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin , 2007, Clinical Cancer Research.

[3]  P. Houghton,et al.  Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  H-l Chen,et al.  Activation of Akt and ERK signalling pathways induced by etoposide confer chemoresistance in gastric cancer cells. , 2006, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[5]  T. Fojo,et al.  Increased MDR1 Expression in Normal and Malignant Peripheral Blood Mononuclear Cells Obtained from Patients Receiving Depsipeptide (FR901228, FK228, NSC630176) , 2006, Clinical Cancer Research.

[6]  M. Kohno,et al.  Blockade of the ERK pathway markedly sensitizes tumor cells to HDAC inhibitor-induced cell death. , 2006, Biochemical and biophysical research communications.

[7]  J. Zalcberg,et al.  Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs , 2005, Oncogene.

[8]  P. Dent,et al.  Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells , 2005, Leukemia.

[9]  M. Grever,et al.  Chemoresistance to Depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-Ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] Is Mediated by Reversible MDR1 Induction in Human Cancer Cell Lines , 2005, Journal of Pharmacology and Experimental Therapeutics.

[10]  J. Byrd,et al.  Efflux of Depsipeptide FK228 (FR901228, NSC-630176) Is Mediated by P-Glycoprotein and Multidrug Resistance-Associated Protein 1 , 2005, Journal of Pharmacology and Experimental Therapeutics.

[11]  S. Bates,et al.  T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. , 2004, Blood.

[12]  J. Toguchida,et al.  FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells , 2003, Oncogene.

[13]  R. Birge,et al.  Fas engagement induces neurite growth through ERK activation and p35 upregulation , 2003, Nature Cell Biology.

[14]  J. Schlegel,et al.  In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways , 2002, Oncogene.

[15]  J. Marshall,et al.  A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. , 2002, Journal of experimental therapeutics & oncology.

[16]  L. Neckers,et al.  Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. , 2002, Journal of the National Cancer Institute.

[17]  S. Bates,et al.  Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  A. Wolffe,et al.  Precipitous Release of Methyl-CpG Binding Protein 2 and Histone Deacetylase 1 from the Methylated Human Multidrug Resistance Gene (MDR1) on Activation , 2002, Molecular and Cellular Biology.

[19]  K. Oka,et al.  Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA , 2002, Cancer Chemotherapy and Pharmacology.

[20]  S. Kimura,et al.  The MEK1‐ERK MAP kinase pathway and the PI 3‐kinase‐Akt pathway independently mediate anti‐apoptotic signals in HepG2 liver cancer cells , 2001, International journal of cancer.

[21]  F. Aoudjit,et al.  Matrix Attachment Regulates FAS-Induced Apoptosis in Endothelial Cells , 2001, The Journal of cell biology.

[22]  V. L. Johnson,et al.  MAPK/ERK signaling in activated T cells inhibits CD95/Fas‐mediated apoptosis downstream of DISC assembly , 2000, The EMBO journal.

[23]  P. Marks,et al.  Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. , 2000, Journal of the National Cancer Institute.

[24]  F. Martinon,et al.  The caspase-8 inhibitor FLIP promotes activation of NF-κB and Erk signaling pathways , 2000, Current Biology.

[25]  Y. Ikawa,et al.  Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase activation. , 2000, Cancer research.

[26]  G. Laurent,et al.  The phosphoinositide 3‐kinase/Akt pathway is activated by daunorubicin in human acute myeloid leukemia cell lines , 1999, FEBS letters.

[27]  J. Girault,et al.  The ERK/MAP-kinases cascade in the nervous system. , 1999, Neuroreport.

[28]  R. Schmidt-Ullrich,et al.  The roles of signaling by the p42/p44 mitogen-activated protein (MAP) kinase pathway; a potential route to radio- and chemo-sensitization of tumor cells resulting in the induction of apoptosis and loss of clonogenicity , 1998, Leukemia.

[29]  N. Holbrook,et al.  The cellular response to oxidative stress: influences of mitogen-activated protein kinase signalling pathways on cell survival. , 1998, The Biochemical journal.

[30]  K. Scotto,et al.  Transcriptional Regulation of the MDR1 Gene by Histone Acetyltransferase and Deacetylase Is Mediated by NF-Y , 1998, Molecular and Cellular Biology.

[31]  K. Paull,et al.  P-glycoprotein substrates and antagonists cluster into two distinct groups. , 1997, Molecular pharmacology.

[32]  S. Nagata,et al.  Apoptosis by Death Factor , 1997, Cell.

[33]  S. Nagata,et al.  Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells. , 1996, Journal of immunology.

[34]  M. Grever,et al.  Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. , 1994, Molecular pharmacology.

[35]  Y. Iwamoto,et al.  Involvement of P‐glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug‐resistant osteosarcoma and Ewing's sarcoma cells , 2006, International journal of cancer.

[36]  K. Watanabe,et al.  Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP , 2005, Cell Death and Differentiation.

[37]  T. Litman,et al.  Efflux of Rhodamine From CD56+ Cells as a Surrogate Marker for Reversal of P-Glycoprotein–Mediated Drug Efflux by PSC 833 , 1999 .

[38]  T. Litman,et al.  Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833. , 1999, Blood.